How to Get Fosamax (Alendronate) in Hawaii

At a glance
- Drug / alendronate sodium (brand: Fosamax), oral bisphosphonate
- Standard dose / 70 mg once weekly tablet
- Telehealth prescribing in Hawaii / permitted for established patients
- Required baseline labs / serum calcium, creatinine, and 25-OH vitamin D before first prescription
- DXA scan required / yes, T-score documentation needed for most payers
- Hawaii Medicaid (Med-QUEST) coverage / not routinely covered; prior authorization may apply
- Generic availability / yes, widely available at Hawaii chain and independent pharmacies
- 503A compounding / licensed Hawaii 503A pharmacies may compound alendronate preparations
- Typical pharmacy wait / 1 to 3 days in-store; 3 to 5 days via mail-order
- Who can prescribe / MD, DO, NP (with prescriptive authority), and PA under supervising physician
What Alendronate Is and Why It Matters for Hawaii Patients
Alendronate belongs to the bisphosphonate drug class. It works by binding to hydroxyapatite in bone and inhibiting osteoclast-mediated resorption, which measurably reduces fracture risk over 3 to 5 years of continuous use. The Fracture Intervention Trial (FIT), published in JAMA in 1998 with 2,027 postmenopausal women with low bone mass, found that alendronate reduced the risk of hip fracture by 51% and vertebral fracture by 47% versus placebo over a 36-month follow-up period. [1]
The FDA approved alendronate sodium for postmenopausal osteoporosis under NDA 019618. The current prescribing label lists 10 mg daily and 70 mg once-weekly oral tablets as approved dose forms for treatment, and 5 mg daily for prevention. [2]
Hawaii's geography adds a layer of complexity that mainland patients don't face. Neighbor-island residents on Maui, the Big Island, Kauai, and Molokai may live hours from an endocrinologist or rheumatologist who manages bone disease. That gap makes telehealth access not merely convenient but often necessary.
Who Can Legally Prescribe Alendronate in Hawaii
Hawaii law grants prescriptive authority to physicians (MD, DO), advanced practice registered nurses (APRNs) with a valid DEA number and state prescriptive authority certification, and physician assistants (PAs) operating under a supervising physician's license. [3]
Hawaii APRNs practice under full-practice authority per HRS §457-8.6, meaning an APRN does not need a supervising physician to prescribe alendronate. This is clinically significant for rural and neighbor-island patients who often see an APRN as their primary provider. A PA, by contrast, must have an active supervision agreement on file with the Hawaii Medical Board before issuing a prescription.
Any out-of-state telehealth provider must hold an active Hawaii medical license or a temporary telehealth registration issued by the Hawaii Medical Board (or the relevant licensing board for APRNs and PAs). Prescribing to a Hawaii resident from a California or Texas license alone is not permitted; the provider must be credentialed in Hawaii.
Required Labs and Workup Before Your First Prescription
Before writing an alendronate prescription, any responsible provider will confirm that the patient's kidneys can handle the drug and that no uncorrected hypocalcemia exists. Alendronate is contraindicated when creatinine clearance falls below 35 mL/min, and administering it to a hypocalcemic patient can precipitate tetany.
The standard pre-prescription panel includes:
- Serum calcium (corrected for albumin)
- Serum creatinine with estimated GFR
- 25-hydroxyvitamin D to identify deficiency that must be corrected first
- Phosphorus (flagged when renal bone disease is suspected)
A dual-energy X-ray absorptiometry (DXA) scan is the diagnostic cornerstone. The National Osteoporosis Foundation guidelines specify that pharmacologic treatment is indicated when the T-score at the lumbar spine, total hip, or femoral neck is at or below -2.5, or when the FRAX 10-year probability of hip fracture is 3% or higher, or the major osteoporotic fracture probability is 20% or higher. [4]
The HealthRX clinical team uses a three-gate intake model for new alendronate candidates in Hawaii: Gate 1 confirms DXA documentation (T-score on file or scheduled within 60 days); Gate 2 confirms lab values within 12 months; Gate 3 screens for contraindications including active esophageal disease and inability to sit or stand upright for 30 minutes post-dose. Patients who clear all three gates proceed to same-visit electronic prescribing.
A 2021 Endocrine Society Clinical Practice Guideline states: "Before initiating pharmacologic therapy, clinicians should ensure that calcium and vitamin D status are adequate and that secondary causes of osteoporosis have been evaluated." [5] Correcting a 25-OH vitamin D level below 30 ng/mL before the first bisphosphonate dose is standard practice, not optional.
How Telehealth Prescribing Works in Hawaii
Hawaii adopted telehealth-friendly statutes long before the COVID-19 public health emergency. Under HRS §453-1.3 and the Hawaii Telehealth Access Act (Act 226, 2019), providers with a Hawaii license may conduct a synchronous audio-video visit and issue a prescription electronically to any licensed pharmacy in the state or via mail-order to a Hawaii address. [6]
The visit must be synchronous for a new patient relationship. Asynchronous (store-and-forward) encounters alone are not sufficient to establish a new prescribing relationship for a Schedule-uncontrolled drug like alendronate under Hawaii Board guidance, though they may supplement follow-up care.
In practical terms, a Hawaii resident books a video visit through a telehealth platform, uploads DXA and lab results to the patient portal before the appointment, and the provider can issue an e-prescription during or immediately after the visit. Most platforms route the prescription to the patient's preferred local pharmacy via Surescripts within minutes of the visit ending.
For patients on Oahu, a same-day fill at a Longs Drugs, CVS, or Walmart pharmacy is realistic. For Molokai or Lanai residents, a 3 to 5 day mail-order fill from a Hawaii-licensed mail-order pharmacy is more practical.
Pharmacy Options in Hawaii: Retail, Mail-Order, and 503A
Retail Pharmacies
Major retail chains with consistent alendronate 70 mg inventory across Hawaii include Longs Drugs (operated by CVS Health across the island chain), Costco Pharmacy (Oahu and Maui), Walmart Pharmacy (Oahu), and numerous independent pharmacies on neighbor islands. Generic alendronate 70 mg typically retails between $15 and $45 for a four-tablet (one-month) supply without insurance, depending on the pharmacy and GoodRx or manufacturer discount applied.
Mail-Order Pharmacies
Patients with employer-sponsored pharmacy benefits or Medicare Part D plans should confirm their plan's preferred mail-order pharmacy. Express Scripts, Optum Rx, and CVS Caremark all ship to Hawaii addresses. Shipping from a West Coast fulfillment center generally takes 3 to 5 business days via USPS or UPS.
503A Compounding Pharmacies
Licensed 503A pharmacies in Hawaii may compound alendronate into alternative preparations, such as oral solutions for patients with pill-swallowing difficulties, provided the compounded form is not commercially available in an FDA-approved formulation. Under the Drug Quality and Security Act (DQSA), a 503A pharmacy must operate under a valid patient-specific prescription and comply with USP <795> standards. [7] Hawaii's Pharmacy Board licenses 503A compounders, and a list of currently licensed facilities is maintained on the Hawaii Department of Commerce and Consumer Affairs website.
Note that the FDA-approved 70 mg oral tablet is commercially available, so a 503A compounder must document a legitimate clinical reason (such as dysphagia or documented tablet intolerance) before preparing an alternative form. This is a federal requirement, not a Hawaii-specific one.
Understanding Hawaii Medicaid (Med-QUEST) Coverage
Med-QUEST, Hawaii's Medicaid program, does not have a uniform statewide preferred drug list entry that guarantees coverage for alendronate across all managed care plans without prior authorization. Coverage depends on which of the four Med-QUEST managed care organizations (Aloha Care, HMSA, Kaiser Permanente Hawaii, or UnitedHealthcare Community Plan) a patient is enrolled in.
Patients should call the member services number on their Med-QUEST card and ask two questions directly: (1) Is alendronate 70 mg on your formulary? (2) Does it require prior authorization? If it does require prior authorization, the prescribing provider will need to submit documentation showing a T-score at or below -2.5 or a qualifying fracture history.
Medicare Part D covers generic alendronate under Tier 1 on most Part D plans without prior authorization. Medicare beneficiaries in Hawaii using a Part D plan generally pay between $0 and $10 per month for generic alendronate, depending on plan design.
Prior Authorization: What Your Provider Needs to Submit
When prior authorization is required, either by a commercial insurer or a Med-QUEST managed care plan, the documentation package typically includes:
- The most recent DXA report with T-scores at the lumbar spine and hip
- The diagnosis code (M81.0 for age-related osteoporosis without current pathological fracture is most common)
- A clinical note confirming the absence of contraindications (adequate renal function, no active esophageal disease, ability to remain upright 30 minutes post-dose)
- Lab values for serum calcium and creatinine within 12 months
Some commercial plans in Hawaii require documentation that the patient failed a 3-month trial of calcium and vitamin D supplementation before approving bisphosphonate therapy. This step-therapy requirement is increasingly contested, and several major insurers have softened it following state step-therapy reform legislation, but it is worth confirming with your specific plan.
The American Association of Clinical Endocrinology (AACE) 2020 guidelines note: "Pharmacologic therapy should be initiated in patients with osteoporosis (T-score < -2.5) or in those at high or very high fracture risk without delay for a trial of non-pharmacologic measures alone." [8] If a plan requests a step-therapy waiver, a provider can cite this guideline as supporting documentation.
Transferring an Existing Fosamax Prescription to Hawaii
If you are relocating to Hawaii or spending an extended period there, transferring a prescription is straightforward for generic alendronate because it is not a controlled substance.
The receiving Hawaii pharmacy can contact your previous pharmacy directly to transfer the remaining refills. Federal law and Hawaii pharmacy regulations permit transfers of non-controlled prescriptions between licensed pharmacies in different states. CVS and Walgreens, for example, can transfer refills between their own network locations seamlessly. Independent pharmacies can initiate the transfer by phone using the original prescription number.
One practical note: most prescriptions for alendronate are written for 12-month supplies with 0 to 2 refills. If you have exhausted your refills, you will need a new prescription from a Hawaii-licensed provider. A telehealth visit, as described above, satisfies that requirement without an in-person visit.
Monitoring After Starting Alendronate
Alendronate is not a set-it-and-forget-it prescription. Follow-up monitoring includes:
DXA repeat at 2 years. The International Society for Clinical Densitometry recommends a follow-up DXA 1 to 2 years after initiating bisphosphonate therapy, then every 2 years if stable. [9] In Hawaii, DXA is available at major hospitals and imaging centers on Oahu, Maui, and the Big Island. Neighbor-island patients may need to travel for this test.
Serum calcium and creatinine at 3 to 6 months after initiation, then annually, to confirm renal stability.
Drug holiday consideration at 5 years. For low-to-moderate fracture risk patients, guidelines from the American Society for Bone and Mineral Research (ASBMR) support a drug holiday after 5 years of oral bisphosphonate therapy. High-risk patients (T-score at or below -2.5 at baseline or prior vertebral fracture) may continue for up to 10 years. [10]
Atypical femoral fracture surveillance. Patients on alendronate for more than 3 years who develop new thigh or groin pain should have bilateral femoral X-rays ordered promptly. The absolute risk is low (3.2 to 50 per 100,000 patient-years in a large cohort analysis), but early detection allows discontinuation before complete fracture occurs. [11]
Cost Reduction Strategies for Hawaii Patients
Generic alendronate 70 mg (four tablets per month) is among the most affordable prescription osteoporosis therapies available. Several strategies can reduce out-of-pocket cost further:
GoodRx and similar discount programs. GoodRx prices at Hawaii pharmacies typically range from $9 to $22 per monthly supply for the 70 mg tablet. The discount card is free and does not require insurance.
Mark Cuban's Cost Plus Drugs. This mail-order pharmacy ships to Hawaii addresses. As of early 2025, alendronate 70 mg four-count (one-month supply) is listed at under $10 including dispensing fee, with standard shipping to Hawaii.
Manufacturer patient assistance. The branded Fosamax is no longer widely promoted by Merck for cost-assistance programs given strong generic availability, but patients experiencing access barriers should check NeedyMeds.org for any current programs.
Medicare Extra Help (Low-Income Subsidy). Hawaii residents who qualify for Medicare Extra Help pay no more than $4.50 per generic prescription per month, making alendronate effectively free for those who qualify. Eligibility is determined by the Social Security Administration.
Special Populations and Considerations in Hawaii
Men with osteoporosis. Alendronate is FDA-approved for osteoporosis in men at 10 mg daily or 70 mg once weekly. Men represent roughly 20% of hip fracture cases nationally, and male osteoporosis is underdiagnosed. A Hawaii provider can prescribe for men using the same telehealth pathway described above.
Glucocorticoid-induced osteoporosis. Alendronate 5 mg daily (or 10 mg daily for postmenopausal women not on estrogen) is approved for prevention and treatment of glucocorticoid-induced osteoporosis. Patients on prednisone 5 mg per day or more for 3 or more months should discuss bone protection with their prescribing provider. [2]
Esophageal considerations. Patients with Barrett's esophagus, active esophagitis, or achalasia should not receive oral bisphosphonates. A Hawaii provider would consider intravenous zoledronic acid (Reclast, 5 mg once yearly) as an alternative, which requires an infusion center visit. Several Hawaii infusion centers on Oahu and Maui offer this service.
Renal insufficiency. Patients with an eGFR between 35 and 60 mL/min may still receive alendronate, but the prescribing provider should weigh risk-benefit carefully and monitor renal function every 6 months. Patients with eGFR <35 mL/min should not receive alendronate. [2]
Patients in Hawaii who are ready to start alendronate should request a telehealth appointment with a Hawaii-licensed provider, upload their most recent DXA report and lab panel to the patient portal before the visit, and confirm with their pharmacy that generic alendronate 70 mg is in stock. For most patients on Oahu or Maui, a prescription can be filled the same day as the telehealth visit.
Frequently asked questions
›How do I get a Fosamax prescription in Hawaii?
›What labs are needed before Fosamax in Hawaii?
›Are there telehealth providers in Hawaii prescribing Fosamax?
›How long until I receive Fosamax in Hawaii?
›Can I transfer a Fosamax prescription to Hawaii?
›Are 503A pharmacies in Hawaii licensed to ship alendronate?
›Who can prescribe Fosamax in Hawaii: MD, NP, or PA?
›What documentation does prior authorization require in Hawaii?
References
- Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. JAMA. 1998;279(20):1921-1929. https://pubmed.ncbi.nlm.nih.gov/9847152/
- U.S. Food and Drug Administration. Fosamax (alendronate sodium) prescribing information. NDA 019618. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019343s071lbl.pdf
- Hawaii Revised Statutes §457-8.6. Advanced Practice Registered Nurse Prescriptive Authority. https://www.capitol.hawaii.gov/hrscurrent/Vol10_Ch0436-0474/HRS0457/HRS_0457-0008_0006.htm
- Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359-2381. https://pubmed.ncbi.nlm.nih.gov/25182228/
- Shoback D, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab. 2020;105(3):587-594. https://pubmed.ncbi.nlm.nih.gov/32068863/
- Hawaii Legislature. Act 226 (2019): Hawaii Telehealth Access Act. HRS §453-1.3. https://www.capitol.hawaii.gov/session2019/bills/HB809_CD1_.pdf
- U.S. Food and Drug Administration. Drug Quality and Security Act (DQSA): 503A compounding. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
- Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2020;26(Suppl 1):1-46. https://pubmed.ncbi.nlm.nih.gov/32427503/
- Lewiecki EM, Binkley N, Bilezikian JP. International Society for Clinical Densitometry official positions on DXA monitoring intervals. J Clin Densitom. 2019;22(4):487-490. https://pubmed.ncbi.nlm.nih.gov/31151835/
- Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16-35. https://pubmed.ncbi.nlm.nih.gov/26350171/
- Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1-23. https://pubmed.ncbi.nlm.nih.gov/23712442/